Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 May 9:10:44.
doi: 10.1186/1475-2891-10-44.

Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design

Affiliations
Randomized Controlled Trial

Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design

Yeong Rhee et al. Nutr J. .

Abstract

Background: Obesity leads to an increase in inflammation and insulin resistance. This study determined antioxidant activity of flaxseed and its role in inflammation and insulin resistance in obese glucose intolerant people.

Methods: Using a randomized crossover design, nine obese glucose intolerant people consumed 40 g ground flaxseed or 40 g wheat bran daily for 12 weeks with a 4-week washout period. Plasma inflammation biomarkers (CRP, TNF-α, and IL-6), glucose, insulin, and thiobaribituric acid reactive substance (TBARS) were measured before and after of each supplementation.

Results: Flaxseed supplementation decreased TBARS (p = 0.0215) and HOMA-IR (p = 0.0382). Flaxseed or wheat bran supplementation did not change plasma inflammatory biomarkers. A positive relationship was found between TBARS and HOMA-IR (r = 0.62, p = 0.0003).

Conclusions: The results of the study weakly support that decreased insulin resistance might have been secondary to antioxidant activity of flaxseed. However, the mechanism(s) of decreased insulin resistance by flaxseed should be further determined using flaxseed lignan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fasting plasma insulin concentrations before and after each supplementation. Data are presented as mean ± standard error, n = 7-9; Statistical significance level was set at 0.05. *Significantly decreased after 12 weeks of wheat bran supplementation compared to the baseline, p = 0.026. No significant change in plasma insulin concentration after 12 weeks of flaxseed supplementation. No significant differences in plasma insulin concentration between flaxseed and wheat bran supplementation groups
Figure 2
Figure 2
HOMA-IR index before and after each supplementation. Data are presented as mean ± standard error, n = 7-9; Statistical significance level was set at 0.05. *Significantly decreased after 12 weeks of flaxseed supplementation compared to the baseline, p = 0.0382. No significant change in HOMA-IR after 12 weeks of wheat bran supplementation. No significant differences in HOMA-IR between flaxseed and wheat bran supplementation groups
Figure 3
Figure 3
Plasma TBARS concentrations before and after each supplementation1. 1TBARS is an indicator for lipid peroxidation, and it is measured in MDA equivalents. Data are presented as mean ± standard error, n = 7-9; Statistical significance level was set at 0.05. *Significantly decreased after 12 weeks of flaxseed supplementation compared to the baseline, p = 0.0215. No significant change in plasma TBARS concentration after 12 weeks of wheat bran supplementation. No significant differences in plasma TBARS concentration between flaxseed and wheat bran supplementation groups

Similar articles

Cited by

References

    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235–241. doi: 10.1001/jama.2009.2014. - DOI - PubMed
    1. Felber J, Golay A. Pathways from obesity to diabetes. Int J Obes. 2002;26:S39–S45. doi: 10.1038/sj.ijo.0802126. - DOI - PubMed
    1. Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B, Gordon D, Krauss R, Savage P, Smith S, Spertus J, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:e285–e290. doi: 10.1161/CIRCULATIONAHA.105.169405. - DOI - PubMed
    1. Zozulinska D, Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract. 2005;74:S12–S16.
    1. Moon Y, Kim D, Song D. Serum tumor necrosis factor-α levels and components of the metabolic syndrome in obese adolescents. Metabolism. 2004;53:863–867. doi: 10.1016/j.metabol.2004.02.007. - DOI - PubMed

Publication types

MeSH terms